TABLE 1.
Cross-clade inhibition of sCD4-activated fusion by MAb 17b
| Expt | Env | Clade | Coreceptor | % Inhibition at MAb 17b concn of:
|
||
|---|---|---|---|---|---|---|
| 0.1 μg/ml | 0.5 μg/ml | 2.5 μg/ml | ||||
| 1a | LAV | B | CXCR4 | 16 | 65 | |
| SF162 | B | CCR5 | 27 | 62 | ||
| 92HT593.1 | B | CXCR4 | 58 | 100 | ||
| 92UG024.2 | D | CXCR4 | 42 | 80 | ||
| 93BR029.2 | F | CCR5 | 41 | 100 | ||
| 93BR019.10 | F/B | CCR5 | 33 | 80 | ||
| 2b | Ba-L | B | CCR5 | 43 | 90 | |
| 89.6 | B | CXCR4 | 57 | 97 | ||
| 92UG037.8 | A | CCR5 | 47 | 94 | ||
| 93MW965.26 | C | CCR5 | 79 | 98 | ||
| CM235 | E | CCR5 | 0 | 45 | ||
a
HeLa effector cells were transfected with a plasmid expressing the designated Env and then infected with vP11T7gene1. NIH 3T3 target cells were cotransfected with pG1NT7β-gal and either pYF1-fusin (CXCR4) or pGA9-CKR5 (CCR5), as indicated, and then infected with wild-type WR.
b
Identical to experiment 1 except that target cells were transfected with pG1NT7β-gal and then infected with either vCBYF1-fusin (CXCR4) or vvCCR5-1107 (CCR5).